Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
Paul Y. Kwo(Palo Alto University), Barbara Haber(Merck & Co., Inc., Rahway, NJ, USA (United States)), John M. Vierling(Baylor College of Medicine), Brian L. Pearlman(Atlanta Medical Center), Lisa Lupinacci(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marı́a Buti(Vall d'Hebron Hospital Universitari), Lawrence Serfaty(Inserm), Cheng‐Yuan Peng(China Medical University), Frank J. Dutko(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Robertson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Edward Gane(University of Auckland), Jacqueline Gress(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lin Li(Shanghai Jiao Tong University), Stuart Black(Merck & Co., Inc., Rahway, NJ, USA (United States)), Eliav Barr(University of New Mexico), Stephen D. Shafran(University of Alberta), Janice Wahl, Paul Stryszak(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 173
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
|Unknown|2006|940